155 related articles for article (PubMed ID: 35456960)
21. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
22. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
23. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
[TBL] [Abstract][Full Text] [Related]
24. Identification of proteins involved in transcription/translation (eEF 1A1) as an inhibitor of Bax induced apoptosis.
Akintade DD; Chaudhuri B
Mol Biol Rep; 2020 Sep; 47(9):6785-6792. PubMed ID: 32875432
[TBL] [Abstract][Full Text] [Related]
25. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer.
Ma X; Zou L; Li X; Chen Z; Lin Z; Wu X
Cancer Biother Radiopharm; 2019 Apr; 34(3):181-188. PubMed ID: 30855185
[TBL] [Abstract][Full Text] [Related]
27. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Sjöblom L; Saramäki O; Annala M; Leinonen K; Nättinen J; Tolonen T; Wahlfors T; Nykter M; Bova GS; Schleutker J; Tammela TL; Lilja H; Visakorpi T
PLoS One; 2016; 11(3):e0150241. PubMed ID: 26939004
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Imamura R; Kitagawa S; Kubo T; Irie A; Kariu T; Yoneda M; Kamba T; Imamura T
Prostate; 2021 Feb; 81(3):147-156. PubMed ID: 33368414
[TBL] [Abstract][Full Text] [Related]
29. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
[TBL] [Abstract][Full Text] [Related]
30. Elongation factor 1A1 regulates metabolic substrate preference in mammalian cells.
Wilson RB; Kozlov AM; Hatam Tehrani H; Twumasi-Ankrah JS; Chen YJ; Borrelli MJ; Sawyez CG; Maini S; Shepherd TG; Cumming RC; Betts DH; Borradaile NM
J Biol Chem; 2024 Mar; 300(3):105684. PubMed ID: 38272231
[TBL] [Abstract][Full Text] [Related]
31. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
32. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
33. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
34. Expression and Clinical Value of Eukaryotic Translation Elongation Factor 1A1 (EEF1A1) in Diffuse Large B Cell Lymphoma.
Gong T; Shuang Y
Int J Gen Med; 2021; 14():7247-7258. PubMed ID: 34737619
[TBL] [Abstract][Full Text] [Related]
35. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.
Scaravilli M; Porkka KP; Brofeldt A; Annala M; Tammela TL; Jenster GW; Nykter M; Visakorpi T
Prostate; 2015 Jun; 75(8):798-805. PubMed ID: 25731699
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.
Kavya K; Kumar MN; Patil RH; Hegde SM; Kiran Kumar KM; Nagesh R; Babu RL; Ramesh GT; Chidananda Sharma S
Mol Cell Biochem; 2017 Sep; 433(1-2):13-26. PubMed ID: 28386843
[TBL] [Abstract][Full Text] [Related]
37. Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Noble AR; Maitland NJ; Berney DM; Rumsby MG
Br J Cancer; 2018 Jan; 118(2):189-199. PubMed ID: 29136407
[TBL] [Abstract][Full Text] [Related]
38. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
39. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
40. MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.
Sarveswaran S; Ghosh R; Morisetty S; Ghosh J
PLoS One; 2015; 10(4):e0122805. PubMed ID: 25875826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
